Table 2 Summary of the literature: PDLG with malignant astrocytic cells
Number of cases (including our patient) | 15 |
|---|---|
M: F ratio | 12:3 |
Median age (in years); age range (in years) | 43; 19-71 |
Secondary brain involvement | 87% (13/15) |
Secondary spinal cord involvement | 74% (11/15) |
Median survival (in months) | 8 (1-24) |
Median survival without therapy (in months) | 5 (1-7) |
Median survival with radiotherapy only | 12 |
(in months) | |
Median survival with chemotherapy only | 3 |
(in months) | |
- without temozolomide | < 3 |
- including temozolomide | 15 |
Median survival with radio- und chemotherapy (in months) | 11 |
- without temozolomide | 3 |
- including temozolomide (our patient) | 18 |